ALS drug trial ends early after just one participant
NCT ID NCT06910384
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tested a new drug, STR04, in people with ALS, a disease that weakens muscles over time. Only one person took part before the study was stopped early. The goal was to see if the drug was safe and if it could slow down the disease, but no clear results are available due to the small size.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Neuromuscular Research Institute
Austin, Texas, 78759, United States
Conditions
Explore the condition pages connected to this study.